<DOC>
	<DOCNO>NCT02422368</DOCNO>
	<brief_summary>ASTED ( Antioxidant Supplements TED ) trial investigator-initiated , randomize , triple mask , clinical trial select combination vitamin mineral versus placebo patient moderate severe thyroid eye disease . The trial parallel-arm design .</brief_summary>
	<brief_title>The Effect New Antioxidant Combination ( ASTED ) Moderate Severe Thyroid Eye Disease</brief_title>
	<detailed_description>Primary aim : To investigate ASTED compare placebo could affect course TED either enhance improvement prevent worsen patient Moderate severe TED thyroid eye disease ( TED ) base : 1 . Total eye score ( NOSPECS severity score ) 1 Total eye score used ass severity TED , calculate multiply class NOSPECS system1 ( except class 0 ) grade severity ( 0-3 ) , yield maximum total score 63 minimum total score 0 ( high number bad severity ) The overall ophthalmic outcome composite score base multiple item ( Soft tissue , retraction , proptosis , diplopia , corneal involvement ) ; use composite score circumvents problem arise presence improvement one item simultaneous worsen another item . The severity score class 1 , 2 , 3 , 4 also separately compare evaluate effect different treatment sign . 2 . Score thyroid eye disease Quality life questionnaire ( TED-QOL ) 2 . Secondary outcome measure : To compare possible change : 1 . Clinical activity score ( CAS Score ) 3 ( 7 item score begin 10 item score 3 6 month ) 2 . Serum thyroid auto-antibodies ( Anti-thyroid peroxidase ( TPO ) , Anti-thyroglobulin ) 0 , 3 6 month . Thyroid function test ( Free T4 , T3 , TSH ) measure 3 visits0 3 . Side effect</detailed_description>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Graves Ophthalmopathy</mesh_term>
	<mesh_term>Antioxidants</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Moderate severe TED le 18 month duration : Active state ( Clinical activity score 3 ) . No steroid supplement treatment last 6 month . Euthyroidism Age 1870 year . Sightthreatening TED Pregnancy Drug and/or alcohol abuse Severe concomitant illness Inability comply study protocol No informed consent Developing severe TED ( Sight threaten TED ) course trial . Contraindications steroid treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Graves ' ophthalmopathy</keyword>
	<keyword>Antioxidant</keyword>
	<keyword>Activity</keyword>
	<keyword>Severity</keyword>
</DOC>